Skip to content
DataLookout
Menu

NCT07841977

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria shortened, about 1 word
    • Primary completion pushed from Jun 2028 to Dec 2028
    • Trial sites expanded: 0 → 4 locations
    • Start date changed from estimate of Oct 2026 to Oct 1, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change From Baseline in Serum Concentration of Alkaline Phosphate (ALP) at Week 24
Timeframe: Baseline, Week 24
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Timeframe: First dose up to 30 days post last dose (up to 318 weeks)
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
Timeframe: First dose up to 30 days post last dose (up to 318 weeks)

Secondary (3)

Proportion of Participants Achieving the Biochemistry Composite Endpoint at Week 24
Proportion of Participants Achieving ALP Normalization at Week 24
Change From Baseline to Week 24 in Weekly Average Pruritus Numerical Rating Scale (NRS)

Arms and interventions

Seladelpar (SEL) 10 mg + Placebo-to-Match (PTM) Cilofexor (CILO) Dose A + CILO Dose BExperimental

Participants will receive a dose of SEL 10 mg capsule along with PTM CILO Dose A tablets and CILO Dose B tablets, once daily up to 24 weeks. At completion of Week 24, participants will continue in an Active Treatment Extension (ATE) Period, during which they will receive SEL 10 mg along with either CILO Dose A or Dose B at the original randomized dose in a blinded fashion, up to Week 312.

SEL 10 mg + CILO Dose A + PTM CILO Dose BExperimental

Participants will receive a dose of SEL 10 mg capsule along with CILO Dose A tablets and PTM CILO Dose B tablets, once daily up to 24 weeks. At completion of Week 24, participants will continue in an ATE Period, during which they will receive SEL 10 mg along with either CILO Dose A or Dose B at the original randomized dose in a blinded fashion, up to Week 312.

SEL 10 mg + PTM CILO Dose A + PTM CILO Dose BActive comparator

Participants will receive a dose of SEL 10 mg capsule along with PTM CILO Dose A tablets and PTM CILO Dose B tablets, once daily up to 24 weeks. At completion of Week 24, participants will continue in an ATE Period, during which they will initiate open-label SEL 10 mg and be re-randomized in a 1:1 ratio to receive CILO Dose A or Dose B in a blinded fashion, up to Week 312.

PTM SEL 10 mg + PTM CILO Dose A + PTM CILO Dose BPlacebo comparator

Participants will receive a dose of PTM SEL 10 mg capsule along with PTM CILO Dose A tablets and PTM CILO Dose B tablets once daily up to 24 weeks. At completion of Week 24, participants will continue in an ATE Period, during which they will initiate open-label SEL 10 mg and be re-randomized in a 1:1 ratio to receive CILO Dose A or Dose B in a blinded fashion, up to Week 312.

Drugs: Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A

Sites

4 sites in 1 country